Quark Pharmaceuticals Collaborates with University of Michigan for Development of SiRNA Compounds for Noise-Induced Hearing Loss
News Oct 01, 2007
Quark Pharmaceuticals, Inc. has announced that it has signed a collaboration agreement with the University of Michigan Kresge Hearing Research Institute to begin pre-clinical studies of several new siRNA compounds for the treatment of acute hearing loss associated with acoustic (noise-induced) trauma through the inhibition of Quark's targets. These pre-clinical studies will be led by Professor Yehoash Raphael, Ph.D., Department of Otolaryngology at the University of Michigan.
These studies will target several different siRNA-based drug candidates that work by way of inhibition of Quark's target genes for the prevention and treatment of acoustic trauma-induced acute hearing loss. The multi-stage, animal model study will assess the ability to deliver these siRNA compounds to relevant cochlear cells in the inner ear. The efficacy of the selected siRNA compounds before and after acoustic trauma, the residence time of siRNA in the inner ear cells, and the duration of the therapeutic siRNA effect will also be primary focuses of the studies.
Daniel Zurr, CEO of Quark Pharmaceuticals, commented, "The establishment of this significant research collaboration with the University of Michigan enables us to expand our research program aimed at preventing and treating hearing loss. With an estimated 28 million Americans having some degree of hearing loss, this is a significant medical issue in the United States and throughout the world. Moreover, hearing loss is an under-diagnosed and under- treated health issue. Quark continues to draw on its expertise in the development of siRNA-based therapeutics and we continue to broaden our pipeline portfolio to include new drug candidates that act by way of inhibiting our novel targets for this disease and an increasing number of indications with unmet medical needs."
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE
New Blood Test Developed to Diagnose Ovarian CancerNews
Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.READ MORE